Context: Short and long-acting somatostatin (SRIF) analogs are approved for clinical use in
acromegaly. Recent analysis of the relative efficacy of octreotide LAR and lanreotide SR on …

Context The somatostatin analogues octreotide LAR and lanreotide Autogel have been
evaluated for the treatment of acromegaly in numerous clinical trials, with considerable …

Настоящее издание-дополненная и существенно переработанная версия клинических
рекомендаций, опубликованных в предыдущие годы, содержит информацию о …

Aliment Pharmacol Ther 2011; 34: 702–713 Summary Background Polycystic liver diseases
(PCLD) represent a group of genetic disorders in which cysts occur solely in the liver, or …

Abstract Context Somatostatin analogs (SSAs) effectively control growth hormone secretion
in first-and second-line treatment of acromegaly. Their effect on glucose metabolism is still …

Background & Aims Clinical trials have shown that in patients with polycystic liver disease
(PLD), short-term treatment with somatostatin analogues (SAs) reduces liver volumes by …

Клинические рекомендации были составлены ГА Мельниченко, НН Молитвослововой,
ЛЯ Рожинской, ИИ Дедовым в мае 2013 г. В июне 2013 г. разосланы всем остальным …

Long-acting somatostatin analogs (SSA) are widely used for the treatment of acromegaly
achieving biochemical control of the disease in 50–75% of the patients. One of the goals of …

Context: Left ventricular hypertrophy (LVH) and myocardial fibrosis are considered common
findings of the acromegaly cardiomyopathy in echocardiography studies. Objective: To …

Acromegaly is a chronic disease with signs and symptoms due to growth hormone (GH)
excess. The most frequent cause of acromegaly is a GH-producing pituitary adenoma …